HRP20010584B1 - N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance - Google Patents

N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Info

Publication number
HRP20010584B1
HRP20010584B1 HR20010584A HRP20010584A HRP20010584B1 HR P20010584 B1 HRP20010584 B1 HR P20010584B1 HR 20010584 A HR20010584 A HR 20010584A HR P20010584 A HRP20010584 A HR P20010584A HR P20010584 B1 HRP20010584 B1 HR P20010584B1
Authority
HR
Croatia
Prior art keywords
piperidinyl
propoxy
pyridine
hydroxy
oxide
Prior art date
Application number
HR20010584A
Other languages
English (en)
Croatian (hr)
Inventor
Kuerthy Maria
Biro Katalin
Nagy Karoly
Ueroegdi Laszlo
Csakai Zita
Szilbereky Jenoe
Mogyoroesi Tamaes
Toeroek Magdolna
Komaeromi Andraes
Maervaenyos Ede
Barabaes Mihaely
Kardos Mihaelynee
Nagy Zoltan
Koraenyi Laeszloe
Nagy Melinda
Original Assignee
Cytrx Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corporation filed Critical Cytrx Corporation
Publication of HRP20010584A2 publication Critical patent/HRP20010584A2/hr
Publication of HRP20010584B1 publication Critical patent/HRP20010584B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20010584A 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance HRP20010584B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (2)

Publication Number Publication Date
HRP20010584A2 HRP20010584A2 (en) 2002-08-31
HRP20010584B1 true HRP20010584B1 (en) 2010-08-31

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010584A HRP20010584B1 (en) 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Country Status (27)

Country Link
US (1) US6649628B1 (ja)
EP (1) EP1163224B1 (ja)
JP (1) JP4689838B2 (ja)
KR (1) KR100676124B1 (ja)
AT (1) ATE237590T1 (ja)
AU (1) AU779096B2 (ja)
BG (1) BG65178B1 (ja)
BR (1) BR0008969A (ja)
CA (1) CA2360451C (ja)
CZ (1) CZ297386B6 (ja)
DE (1) DE60002187T2 (ja)
DK (1) DK1163224T3 (ja)
EE (1) EE04961B1 (ja)
ES (1) ES2193055T3 (ja)
HR (1) HRP20010584B1 (ja)
HU (1) HUP9900475D0 (ja)
IL (2) IL144866A0 (ja)
NO (1) NO319793B1 (ja)
PL (1) PL197692B1 (ja)
PT (1) PT1163224E (ja)
RS (1) RS50083B (ja)
RU (1) RU2250901C2 (ja)
SI (1) SI1163224T1 (ja)
SK (1) SK287063B6 (ja)
UA (1) UA72495C2 (ja)
WO (1) WO2000050403A1 (ja)
ZA (1) ZA200106488B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
AU2003202104B8 (en) * 2002-01-11 2008-10-02 Cytrx Corporation Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
US8540985B2 (en) 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
EP2356988A4 (en) * 2008-11-18 2012-05-09 Santen Pharmaceutical Co Ltd THERAPEUTIC FOR CHORIORETINAL DEGENERATION WITH PYRIDINE-3-CARBALDEHYDE O- (PIPERIDIN-1-YL-PROPYL) OXIM DERIVATIVE AS ACTIVE SUBSTANCE
PT2646044T (pt) 2010-11-30 2019-11-12 Orphazyme As Métodos para aumentar a atividade intracelular de hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
US9861654B2 (en) * 2012-09-06 2018-01-09 Mcpharma Biotech Inc. Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
HUE034782T2 (en) 2012-09-14 2018-02-28 Saint Gobain Shield with electrical connector
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
PT3193840T (pt) * 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
CA3063974A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
EP4171559A1 (en) 2020-06-24 2023-05-03 Zevra Denmark A/S Arimoclomol for treating gaucher disease
EP4247792A1 (en) * 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
WO2022136640A1 (en) 2020-12-24 2022-06-30 Orphazyme A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004584A1 (en) * 1988-10-20 1990-05-03 Biorex Kutató Fejleszto^' Kft. Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
WO1997016439A1 (en) * 1995-11-02 1997-05-09 Biorex Kutató és Fejlesztó Rt. Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
WO1998043948A1 (en) * 1997-04-03 1998-10-08 Biorex Kutató És Fejleszto^' Rt. Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004584A1 (en) * 1988-10-20 1990-05-03 Biorex Kutató Fejleszto^' Kft. Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
US5328906A (en) * 1988-10-20 1994-07-12 Biorex Kutato-Fejleszto Kft 0-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
WO1997016439A1 (en) * 1995-11-02 1997-05-09 Biorex Kutató és Fejlesztó Rt. Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
WO1998043948A1 (en) * 1997-04-03 1998-10-08 Biorex Kutató És Fejleszto^' Rt. Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides

Also Published As

Publication number Publication date
ES2193055T3 (es) 2003-11-01
EP1163224A1 (en) 2001-12-19
NO20014103D0 (no) 2001-08-23
IL144866A0 (en) 2002-06-30
ZA200106488B (en) 2002-08-07
CA2360451A1 (en) 2000-08-31
WO2000050403A1 (en) 2000-08-31
CA2360451C (en) 2011-01-04
BG65178B1 (bg) 2007-05-31
NO20014103L (no) 2001-10-22
EP1163224B1 (en) 2003-04-16
SK11582001A3 (sk) 2001-12-03
HUP9900475D0 (en) 1999-04-28
NO319793B1 (no) 2005-09-12
SK287063B6 (sk) 2009-10-07
AU779096B2 (en) 2005-01-06
JP4689838B2 (ja) 2011-05-25
HRP20010584A2 (en) 2002-08-31
PL197692B1 (pl) 2008-04-30
CZ20013053A3 (cs) 2002-01-16
DE60002187T2 (de) 2003-12-11
DK1163224T3 (da) 2003-08-04
UA72495C2 (uk) 2005-03-15
CZ297386B6 (cs) 2006-11-15
IL144866A (en) 2007-07-04
AU3182400A (en) 2000-09-14
ATE237590T1 (de) 2003-05-15
PT1163224E (pt) 2003-07-31
PL350915A1 (en) 2003-02-10
RS50083B (sr) 2009-01-22
RU2250901C2 (ru) 2005-04-27
YU60301A (sh) 2004-05-12
JP2002537384A (ja) 2002-11-05
DE60002187D1 (de) 2003-05-22
BR0008969A (pt) 2001-11-27
BG105837A (en) 2002-03-29
KR100676124B1 (ko) 2007-01-31
EE04961B1 (et) 2008-02-15
SI1163224T1 (en) 2003-08-31
EE200100447A (et) 2002-12-16
KR20010102410A (ko) 2001-11-15
US6649628B1 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
HRP20010584B1 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
DK1204654T3 (da) Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
GB9801690D0 (en) Therapeutic agents
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
CO5031285A1 (es) Triarilimidazoles
TW200407287A (en) A sulfonated amine acid derivative and the metalloproteinase inhibitor containing it (I)
ATE495187T1 (de) Dalda-analoge und ihre verwendung
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
MXPA03002911A (es) Compuestos quimicos.
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
MXPA02012076A (es) Compuestos quimicos.
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA02012659A (es) Derivados de pirazindiona condensados.
RS51003B (sr) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
DK1204659T3 (da) Serotonerge benzofuraner
TR200001121T2 (tr) Antiromatizmal madde.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
SE9902387D0 (sv) New pharmaceutically active compounds
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
ATE74138T1 (de) Heptanoyl-glu-asp-ala-amino-saeureimmunstimulanten.
SE9704770D0 (sv) New use

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: CYTRX CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20100726

Year of fee payment: 8

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20110225